Cyclerion Therapeutics In...

NASDAQ: CYCN · Real-Time Price · USD
3.08
-0.09 (-2.84%)
At close: Jun 06, 2025, 10:01 AM

Company Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.

It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS.

It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc. logo
Country United States
IPO Date Mar 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Dr. Regina M. Graul Ph.D.

Contact Details

Address:
245 First Street
Cambridge, Massachusetts
United States
Website https://www.cyclerion.com

Stock Details

Ticker Symbol CYCN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001755237
CUSIP Number 23255M105
ISIN Number US23255M2044
Employer ID 83-1895370
SIC Code 2834

Key Executives

Name Position
Dr. Regina M. Graul Ph.D. Chief Executive Officer, President & Director
Rhonda M. Chicko CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 07, 2025 8-K Current Report
May 07, 2025 424B5 Filing
May 06, 2025 S-3 Filing
May 06, 2025 10-Q Quarterly Report
Apr 29, 2025 DEFA14A Filing
Apr 29, 2025 DEF 14A Filing
Mar 28, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 27, 2025 4 Filing
Mar 27, 2025 4 Filing